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ABSTRACT
Obstructive sleep apnea (OSA) is estimated to
occur in 26% of adults and 2% to 7% of
children. OSA is characterized by a partial or
complete cessation of airflow in the upper
airway. Classically, the main risk factors
include obesity, age, and gender, although
those outside the ‘‘overweight, middle-aged
man’’ phenotype can certainly be at risk for
the development of OSA, particularly when
predisposing anatomic abnormalities are
encountered. Common symptoms include
excessive daytime sleepiness, snoring,
witnessed apneas, choking or gasping, and
unrefreshing sleep. OSA has also been linked
to many systemic pathology including
pulmonary and cardiovascular disease,
neurocognitive and neuropsychiatric
impairments, metabolic dysregulation, and
ophthalmologic disorders. Due to this
potential for influencing multi-system disease,
accurate diagnosis and treatment is essential.
Treatment methods are continuously
developing and improving, but the traditional,
gold standard treatment is positive airway
pressure (PAP) treatment. There are several
modalities within this category including
continuous PAP and bilevel PAP. Other
treatment alternatives which can improve OSA
include upper airway surgery, orthodontic
therapy, mandibular advancement devices,
and weight loss. Novel treatments that target
upper airway muscle tone include hypoglossal
nerve stimulation and myofunctional exercises.
The goal of this article was to summarize key
aspects of patient presentation, potential
comorbidities, and therapeutic options for
multidisciplinary clinicians who play an
integral role in the management of this
syndrome from childhood to old-age.
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INTRODUCTION
Obstructive sleep apnea (OSA) syndrome is
characterized by repetitive episodes of either
partial (hypopnea) or complete (apnea) collapse
of the upper airway with associated symptoms
[1]. Increased resistance (due to anatomic factors
such as nasal obstruction, lymphoid tissue
hypertrophy) and increased compliance
(increased collapsibility during inspiration) of
theupper airway are among the factors leading to
obstruction during sleep [2]. These events may
lead to oxyhemoglobin desaturations, carbon
dioxide retention, and arousal from sleep [2, 3].
Patients with OSA most commonly complain of
daytime sleepiness and fatigue. Complaints may
also include snoring, choking or gasping,
witnessed apneas, morning headaches, and
non-restorative sleep [2, 4].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RISK FACTORS
Anatomy, obesity, gender, and age are all
important risk factors when screening patients
for OSA. Anatomically, many OSA patients
often have a smaller upper airway compared to
normal subjects. Deficits in maxillary and
mandibular development can restrict the size
of the upper airway [2, 4, 5]. An increase in the
size of the soft tissues such as the tongue and
lateral pharyngeal walls causes a decrease in
airway circumference, thus increasing resistance
[2, 4, 5]. Presence of lymphoid tissue (adenoids,
tonsils) is an important anatomic finding that
may increase the risk of OSA, particularly in the
pediatric population [4]. A careful physical
exam with attention to these factors is
important when considering a diagnosis of
OSA.
OSA does indeed have an intimate
association with obesity. Studies have linked
obesity with increased fat deposits in the lateral
parapharyngeal fat pads and the tongue, which
reduces the pharyngeal airway size and
increases the size of the soft tissues,
respectively [2, 4]. This becomes problematic
because the tongue plays an important role in
pharyngeal dilation, but fat deposits may
inhibit muscle function as well as decrease
airway size and increase collapsibility [6].
Gender differences have also been implicated
as factors in OSA. Women have smaller upper
airway, neck, tongue, and soft tissue sizes than
men [4]. During puberty, adolescent boys have a
longer pharyngeal airway, resulting in increased
airway collapsibility [7, 8].
Aging also impacts OSA development for
several reasons. Studies have reported that
aging increases the risk of developing OSA due
to shortening of the anterior–posterior length of
the structures around the pharynx. This, in turn,
may affect reflexes controlling airway patency,
allowing the pharyngeal airway to become more
collapsible. Furthermore, increased fat deposits
around the upper airway during aging can lead to
restricted air flow as seen in obesity. Moreover,
whereasmales show increasedpharyngeal airway
length early in life, females develop long
pharyngeal airways and larger tongues around
the time of menopause [8].
DIAGNOSIS
While OSA remains persistently underdiagnosed,
recentestimates suggest that27%ofmenand11%
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ofwomenbetween theagesof 30and70haveOSA
[9]. OSA can occur at any age (2% to 7% of
children) but is more common in middle and
older age [2, 5]. Underdiagnosis of OSA is
common, with symptoms associated with the
disorder often mistakenly attributed to other
neurological or psychiatric disorders [10]. It is
thus important for healthcare professionals to be
awareof the symptomsand treatments forOSA, as
this disorder can severely diminish quality of life.
The importance of accurate diagnosis is perhaps
not better highlighted than with the risk of
drowsy driving and motor vehicle collisions in
untreated patients with OSA [11].
In addition to salient features of the history
and physical, diagnostic polysomnography is an
essential tool in the diagnosis of OSA (Table 1).
Breathing events can be quantified during
polysomnography, with summary reports
including measurements such as the Apnea
Hypopnea Index (AHI: number of apneas in
addition to hypopneas per hour) and Oxygen
Desaturation Index (ODI: number of
oxyhemoglobin desaturations per hour
observed during monitoring). Obstructive
apneas are noted when there is at least a 90%
drop in airflow associated with ongoing
respiratory muscle effort [3]. Hypopneas are
scored when there is at least a 30% drop in
airflow, resulting in either an associated
oxyhemoglobin desaturation or
electroencephalographic arousal [3]. Other
abnormalities in airflow measurements (such
as flow limitation) leading to disruption of sleep
not meeting the above criteria may also be
reported as part of a Respiratory Disturbance
Index (RDI) [3]. Through these measurements,
an interpretive report attempts to summarize
the presence and severity of sleep apnea from
the overnight recording. This report, in
addition to the history and physical
examination, helps the clinician to make a
diagnosis of OSA. [3]. By confirming the
diagnosis and initiating treatment, the
clinician can address the patients’ chief
complaints, as well as mitigate the potential
impacts of OSA on systemic disease.
OSA AND ASSOCIATED
MORBIDITY: MORE THAN JUST
SNORING
The growing associations between OSA and
systemic diseases have broadened the rationale
Table 1 Key points in the history and physical exam of
patients with suspected OSA
History
Partner or caretaker report of snoring, pauses, or
gasping during sleep
Fragmented sleep










Nasal septal deviation, turbinate hypertrophy, or valve
collapse
Elevated Modiﬁed Mallampati score




OSA obstructive sleep apnea
a Primarily seen among children
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for therapy beyond simply targeting snoring
and daytime sleepiness. As a result, referrals to
sleep physicians now come from a variety of
sources, including both primary care providers





An increase in cardiovascular disease is
predicted by the presence of OSA. This has
been suggested to be mediated by a variety of
mechanisms including increased sympathetic
tone [12], endothelial dysfunction [13, 14], and
platelet aggregation [15]. As a result, referrals to
sleep physicians are increasingly common from
primary care providers and cardiovascular
specialists hoping to better address their
patients’ risk factors for hypertension, stroke,
and arrhythmia [16].
A dose–response association between the
number of breathing events per hour on a
diagnostic polysomnogram and the incidence
of hypertension at four-year follow-up was
demonstrated among participants in the
Wisconsin Sleep Cohort Study [17]. While the
odds ratios (ORs) for incident hypertension
were strongest among those with an AHI of 15
events per hour or more [OR 2.89, 95%
confidence interval (CI) 1.45–5.64], there was
a significant association even among those with
an AHI of 0.1 to 4.9/h (OR 1.42, 95% CI
1.13–1.78) relative to subjects with an AHI of
0/hr. Cardiac arrhythmias, including atrial
fibrillation, are known to be associated with
the presence of OSA [18] with some evidence
suggesting that the treatment of OSA may
reduce the frequency of arrhythmias [19].
Additionally, patients with OSA are at an
increased risk (relative risk 2.57) of sudden
cardiac death during typical sleeping hours
(12:00AM–5:59AM) contrary to those without
OSA who were more likely to have a fatal event
in the morning hours (6:00AM–11:59AM) [20].
Treatment of OSA with continuous positive
airway pressure (CPAP) has been associated




While excessive daytime sleepiness is a cardinal
daytime symptom among patients with OSA,
other neurocognitive and neuropsychiatric
complaints are frequently reasons for
presentation to the sleep clinic. An analysis of
190 subjects with OSA demonstrated that
patients often reported ‘‘lack of energy’’ or
‘‘tiredness’’ as opposed to ‘‘sleepiness’’ as their
principal daytime complaint [22]. Treatment
with CPAP demonstrated significant
improvement in objective measurements of
fatigue and energy compared to placebo-CPAP
after only 3 weeks of therapy [23].
OSA has also been associated with
impairments in cognitive function, including
the domains of executive function, memory,
and attention [24–27]. In the pediatric
population, symptoms of OSA and attention
deficit hyperactivity disorder overlap, and
screening for sleep-disordered breathing
should be considered in this population [28].
The association between OSA and the
development of dementia has also been a
focus of recent attention, with one study
suggesting that older women with an ODI of
[15/h were at an increased risk for developing
dementia (OR 2.04, 95% CI 1.10–3.78) [29]. A
small study including participants with mild to
moderate Alzheimer’s disease who continued
with CPAP use through a three-year follow-up
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demonstrated less cognitive decline compared
to subjects who discontinued therapy [30].
An association between OSA and depression
has also been suggested in the literature.
Participants in the Wisconsin Sleep Cohort
Study demonstrated a relationship between
sleep apnea severity at baseline and future risk
of developing depressive symptoms [31]. A
review of the National Health and Nutrition
Examination Survey 2005–2008 survey data also
suggests an association between survey-based
indicators of OSA and depression in a sample of
11,329 adults [32]. However, the data are mixed
with regard to the effects of treatment of OSA
on outcomes associated with depression [33,
34]. Kawahara et al. found that CPAP treatment
lessened participants’ scores on the Epworth
Sleepiness Scale (ESS) and the Sung
self-depression scale [33]. Gagnadoux et al.
reported that after 1 year of CPAP treatment,
persistent depressive symptoms were not
resolved by treatment but were associated with
ESS score [34]. This suggests that CPAP therapy
may help with depressive symptoms if it is
effective in lowering the ESS score.
Pulmonary Disease
While the relationship between OSA and
obstructive lung diseases such as asthma and
chronic obstructive pulmonary disease (COPD)
is not fully understood, studies have
demonstrated the importance of OSA
diagnosis and treatment in patients with
obstructive lung diseases. The Sleep Heart
Health study looking at the overlap between
OSA and COPD reported that patients who had
both airflow obstruction as well as a RDI[10/h
scored higher on the ESS, had less sleep time
and efficiency, and had more oxygen
desaturations compared to patients with either
airflow obstruction or an RDI[10 [35].
Metabolic Dysregulation
Insulin resistance and impaired glucose
metabolism have been shown to be associated
with OSA, even when controlling for body mass
index [36, 37]. Researchers have proposed that
OSA increases stress on the body leading to the
development of these conditions. Treatment of
OSA has been associated with improvements in
insulin resistance [38]. Patterns of fat
distribution also may be driven by the
presence of OSA, with one study suggesting
that increased visceral fat deposition is more
strongly associated with obese patients with
OSA than obese controls [39].
Ophthalmologic Disorders
Ophthalmologic disorders and the potential
link to OSA has been a target of increasing
focus. The bulk of the focus has targeted the
potential association between OSA and the
development of glaucoma, with mixed data
suggesting both the presence [40, 41] and
absence [42] of a significant link. One study
based in France found no difference in
incidence of glaucoma between participants
with and without OSA [42]. However, another
study based in Taiwan found that within a
five-year follow-up period participants with
OSA had a 1.67 hazard ratio for glaucoma
compared to participants without OSA [40].
An association between OSA and other
ophthalmologic disorders, such as floppy
eyelid syndrome [43, 44], optic neuropathy
[45, 46], and papilledema [47] has also been
suggested in the literature.
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TREATMENT OPTIONS
CPAP: Tried-and-True
CPAP is currently the most effective treatment
for OSA and is regarded as the gold standard
[48]. Sullivan, in 1981, first demonstrated that
CPAP prevents obstructive events by
maintaining upper airway patency during
sleep with delivered air pressure [49]. Goel
et al. report specifically that using CPAP for a
minimum of 4 h significantly improved
symptoms such as daytime sleepiness and
exercise capacity [50]. On the other hand,
Weaver et al. showed that the cut-off point of
4 h is artificial, and all night usage is the goal
[51]. Following 1 year of CPAP use, studies have
demonstrated significant improvement in
quality of life, decrease in ESS score, and
improvement in blood pressure [52, 53].
Throughout the past decades, PAP therapy
has made vast improvements not only in
pressure delivery, patient comfort, and
accessibility. Older devices were large, heavy,
loud, and did not provide feedback on
compliance or effectiveness (Fig. 1). Devices
are now much smaller, portable, and quiet.
Current machines can report usage, mask fit,
and AHI to the patient and prescriber. In
addition, newer devices allow physicians to
remotely monitor use and efficacy, as well as
adjust settings. Many devices now have
algorithms to auto-adjust pressures in relation
to detected obstructive events. These devices
can increase pressures during periods of sleep
where obstruction may be more prominent
(e.g., rapid eye movement sleep or supine
position sleep), and decrease when obstruction
is less problematic. This may potentially
increase the tolerability of PAP therapy [54].
While PAP therapy has evolved, adherence
remains as a primary obstacle to therapy.
Factors impacting adherence include nasal
resistance, optimal pressures, mask fit, and
adverse side effects [55]. To mitigate these
issues, allergies, nasal congestion, and nasal
septum deviation should be well treated.
Physicians should work with patients to find
the most comfortable and effective pressures,
proper mask fittings should be employed, and
side effects should be minimalized. Sleeping
positions such as elevation of head and trunk
may help reduce nasal resistance [56].
Alternatives to PAP Therapy: It Takes
a Village
While PAP therapy is considered the treatment
of choice for OSA, alternative therapies may be
a consideration based on treatment preference
and disease context [48]. Pursuing these
treatment options requires a multi-disciplinary
approach, involving otolaryngologists, general
surgeons, orthodontists, oral and maxillofacial
surgeons, dentists, and nutritionists.
Fig. 1 One of the ﬁrst continuous positive airway pressure
(CPAP) machines used in the United States, weighing 12
kilograms. Equipment was created at the Stanford Sleep
Clinic in December 1981 based on advice from Colin
Sullivan, MD (University of Sydney, Australia). Newer
PAP devices are small, portable, quiet, and provide
objective feedback on use and efﬁcacy
36 Pulm Ther (2015) 1:31–42
Upper Airway Surgery
Surgical interventions, particularly in the realm
of pediatrics, are a mainstay of therapy in the
management of OSA. The American Academy of
Pediatrics recommends adenotonsillectomy for
those with evidence of hypertrophy without
contraindication to surgery as the first line of
treatment for pediatric OSA [57]. For adults (and
much less commonly in select pediatric cases),
uvulopalatopharyngoplasty (UPPP) and tongue
base reduction surgeries may also be a
consideration. However, surgical improvement
(defined as an AHI of\20/h and a decrease of
50% from baseline) was noted in just over 50%
of patients with UPPP in one case series [58].
Even among those with surgical improvement,
some residual disease may remain. Much of this
is due to the fact that soft tissue surgeries may
not address the underlying skeletal
abnormalities that predispose these patients to
the development of upper airway obstruction.
As a result, further attention has been
directed to skeletal based surgeries.
Maxillomandibular advancement (MMA),
achieved by osteotomy of the maxilla and
mandible, increases airway dimensions and
decreases airway resistance. A meta-analysis
demonstrated favorable surgical success rates
(86.0%) for patients undergoing the procedure
[59]. Moreover, 43% of patients attained
surgical cure (AHI \5/h), with the mean AHI
decreasing from 63.9 (±26.7/h) pre-MMA to 9.5
(±10.7/h) post-MMA surgery.
Orthodontic Therapy
Rapid maxillary expansion in pediatric
orthodontics has played an important role in
the management of malocclusion and dental
crowding. However, recent evidence suggests
that palatal expansion plays an important role
in the management of pediatric OSA, taking
advantage of the not yet fused maxillary suture.
Maxillary expansion has been associated with
cephalometric increases in nasal base and nasal
cavity, thereby decreasing total airway resistance
[60]. A study involving 31 children between the
ages of 5 and 8 who underwent rapid maxillary
expansion resulted in AHI improvement that
continued through adulthood [61] (Fig. 2).
Surgically assisted rapid maxillary expansion
may be a consideration in adults once the
palatal suture has fused, with data suggesting a
56% reduction in AHI and significant
improvement in validated measures of
sleepiness after the procedure [62].
Mandibular Advancement Devices
Oral appliances, targeting anterior
advancement of the mandible, have been used
as an alternative to PAP therapy for decades
[63]. These custom devices, fashioned by a
dentist, work by enlarging the oropharyngeal
airway. These can be considered as an initial
treatment for patients with mild to moderate
OSA who elect to defer treatment with PAP
therapy [48]. The use of Mandibular
Advancement Devices (MAD) was associated
with a 62.5% improvement in AHI among
patients with OSA in a randomized controlled
trial, with 37.5% demonstrating complete
response (a treatment AHI\5/h) [64]. Another
Fig. 2 Example of Rapid Maxillary Expansion in a child
with high-arched palate
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randomized controlled trial demonstrated
improvement in measures of objective and
subjective sleepiness with MAD use [65]. While
this may be an attractive option for patients,
potential limitations such as aggravation of the
temporomandibular joint, occlusal changes,
tooth discomfort, and sub-optimal therapy
may make this a less desirable treatment
option for some patients [66].
Weight Loss and Bariatric Surgery
Obesity has been consistently shown to be an
independent (although not the solitary)
predictor of OSA. While achieving weight loss
through behavioral or dietary interventions may
be challenging, small reductions in weight can
make a significant impact on the severity of
associated OSA. In a prospective cohort of 690
subjects followed over a 4-year period, a 10%
reduction in body weight was associated with a
26% decrease in AHI (a 20% reduction was
associated with a 48% decrease in AHI) [67]. As
a result, attention to weight reduction should be
a part of the treatment discussion for overweight
and obese patients with OSA. The role of
bariatric surgery should be part of this
discussion. A clinical trial comparing lifestyle
modification to bariatric surgery among 133
morbidly obese patients with OSA
demonstrated favorable improvements in
weight status (30% vs. 8% weight reduction)
and AHI among those undergoing surgical
intervention [68]. Among those undergoing
bariatric surgery, 66% had remission of OSA.
Emerging Therapies for OSA: Strength
in Muscles
While many of the previously discussed
therapies target mechanical solutions to upper
airway obstruction, attention is being directed
towards emerging strategies that address
underlying neuromuscular weakness that is a
major component of OSA.
Myofunctional Therapy
Myofunctional therapy, utilizing a series of
coordinated exercises to strengthen orofacial
muscles, has been discussed in the literature as a
means of targeting orthodontic issues such as
malocclusion for a century [69]. The effects of
adjacent muscles on occlusal status and jaw
growth suggest that there may be a role for
targeting tone and position of these muscles to
improve airway patency during sleep in patients
with OSA [70]. A number of studies have now
suggested demonstrable improvements in
objective measures among patients with OSA
undergoing a regimented myofunctional
exercise program [70–72]. A recent
meta-analysis of myofunctional therapy in the
treatment of OSA demonstrated a reduction in
AHI by 50% in adults and 62% in children [73].
This suggests an important treatment and
prevention option, particularly among
children where the trajectory of jaw growth is
still dynamic. Furthermore, a common source
of airway obstruction during sleep is when the
tongue relaxes and shifts into a more posterior
position, thus blocking the airway.
Myofunctional therapy trains and strengthens
the tongue muscle to prevent this obstruction.
Hypoglossal Nerve Stimulation
Collapsibility of the upper airway muscles
(particularly the genioglossus) is thought to be
a major contributing factor to OSA, and
contraction has been demonstrated to improve
airway patency [74, 75]. In recent years,
implantable Hypoglossal Nerve Stimulation
(HNS) has been approved for use in patients
who fail first line therapies for OSA. A
meta-analysis including 200 patients who
underwent implantation of a HNS
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demonstrated an approximate 50% reduction in
AHI and ODI following placement [76]. The
generalizability of these data remains to be seen
as most studies had very stringent inclusion
criteria [76]. However, this may be a reasonable
option for patients who have failed alternative
modalities of therapy.
CONCLUSION
The impacts of untreated OSA on systemic
health cannot be understated. As the
pathophysiology of OSA is further elucidated,
the impacts on health will likely only become
more profound. As a result, identification of
patients by primary care providers and
sub-specialists will be essential in managing
co-morbid and associated conditions.
Given the anatomic and skeletal influences
on the development of OSA, recognizing the
process early in childhood may allow for an
opportunity to reverse this trajectory.
Pediatricians and orthodontists may have a
unique role in managing this preventative
strategy by identifying patients who may
benefit from treatment options such as
myofunctional therapy and palatal expansion
that address underlying issues with jaw growth.
Personalized medicine will likely play a more
pivotal role in the management of patients with
OSA. As treatment options expand, a ‘‘one size
fits all’’ approach will no longer suffice. As such,
a multi-disciplinary team will be essential to
maximizing treatment efficacy for patients with
OSA.
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